• Merck secured European Commission approval for Keytruda with Padcev as treatment before and following surgery for adults with resectable muscle-invasive bladder cancer.
• The regimen becomes the EU’s first PD-1 inhibitor–antibody-drug conjugate combination for this population regardless of eligibility for cisplatin chemotherapy.
• Previously reported Phase 3 KEYNOTE-B15 results showed improved survival and reduced disease progression or recurrence versus chemotherapy with surgery in cisplatin-eligible patients.
• The authorization covers all 27 EU member states, Iceland, Liechtenstein and Norway; commercial availability depends partly on national reimbursement procedures.
• U.S. regulators cleared the regimen for adults with muscle-invasive bladder cancer regardless of cisplatin eligibility in July 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck & Co. Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610210645BIZWIRE_USPR_____20261021_BW594617) on October 21, 2026, and is solely responsible for the information contained therein.